FierceBiotech1d
Eli Lilly's next R&D focus: Testing incretin meds in neuro, immunology fields
Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...
Yahoo Finance21d
Lexaria's Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half with Comparable Efficacy Versus Eli Lilly's Injectable GLP-1/GIP Drug Zepbound(R)
One objective of diabetes drugs is to assist the body in producing more insulin to better control blood glucose levels. The mean baseline blood insulin levels (expressed in µU/mL) were 11.2±4.1 ...
FDA approves Novo Nordisk's Ozempic to treat chronic kidney disease in those with diabetes, expanding its use
Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...
KSL29d
Eli Lilly's obesity drug gets Medicare coverage for sleep apnea
WASHINGTON — Eli Lilly's obesity ... rival Novo Nordisk's obesity drug Wegovy also gained Medicare coverage to reduce the risk of heart attacks and strokes. Lilly and Novo are testing ...
biznews.com17d
🔒 FT: Weight-loss drugs reduce risk of Alzheimer’s, large study shows
A study shows GLP-1 weight-loss drugs reduce Alzheimer’s risk but increase arthritis, kidney, and pancreas issues.
FiercePharma17d
Large study of Novo, Lilly weight loss drugs shows decrease in risk of Alzheimer's
As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has approved Novo Nordisk’s semaglutide for heart disease and Eli Lilly’s ...